MyPath Melanoma is a gene expression profile (GEP) test that provides clarity in managing patients with ambiguous melanocytic lesions.
When patients are diagnosed with routine nevi or malignant melanoma, the treatment plans are clearly defined by medical guidelines. However, there is a lack of clarity and standardization in the most appropriate management plan for patients with ambiguous, atypical, and abnormal melanocytic lesions. MyPath Melanoma can clarify the underlying malignant potential of the lesion allowing providers to escalate or de-escalate surgical treatment and follow-up frequency.


In recent studies and case reports, 1,2 ancillary diagnostic GEP testing has aided dermatologists in determining the malignant potential of these challenging melanocytic lesions. This allows providers to confidently align patient management to the malignant potential as determined by GEP.
MyPath Melanoma GEP testing provides an objective assessment of the expression levels of 23 genes and applies a proprietary algorithm to classify the lesion as suggestive of benign or suggestive of malignant.3 Numerous studies have demonstrated high sensitivity and specificity 4-8 and clinical utility 9–12 of GEP testing for dermatology providers.


Learn how MyPath Melanoma provided clarity to a dermatologist when making management decisions for a patient with an ambiguous lesion.


Atypical intraepidermal melanocytic proliferation (AIMP)
Borderline or severely dysplastic nevus
Cannot exclude melanoma in situ
Cannot exclude early-evolving invasive melanoma

Atypical Spitz tumor
Melanocytic tumor of uncertain malignant potential (MELTUMP)

Highly concerning clinical history or dermoscopic features
Critical mismatch between clinical and histopathological findings
Equivocal, ambigious, or indeterminate result from ancillary testing such as IHC, FISH, or CGH

Surgical management in cosmetically sensitive areas
Follow-up management decisions
Recommendation to re excise without definitive diagnosis for melanoma